glp-1 drugs covered by insurance Designing fiscally viable coverage of weight-loss The GLP-1 Access Gap: Mapping

These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity

Muscle loss at this life stage is linked to reduced strength, increased fall risk, metabolic slowdown, and long-term functional decline

October 15, 2025: 133 New Lawsuits Filed for Injuries from Zepbound and Other GLP-1 Drugs Between September and October 2025, 133 lawsuits joined the group litigation for people harmed by Zepbound and other GLP-1 drugs

Da Silva Ferreira, C

Notably, genome-wide association study (GWAS) analyses for body mass index (BMI) have linked glutamatergic signalling and NMDA receptor-related neuroplasticity to regulation of body weight and obesity 1,5